Literature DB >> 7356889

Plasma noradrenaline concentration in essential hypertension during long-term beta-adrenoceptor blockade with oxprenolol.

D H Jones, J Daniel, C A Hamilton, J L Reid.   

Abstract

1. Chronic beta-adrenoceptor blockade with oxprenolol causes elevation of plasma noradrenaline levels, as compared with placebo, despite a significant fall in blood pressure and pulse rate. 2. The plasma noradrenaline concentration is not influenced by the frequency of administration or the formulation of the drug. 3. Plasma noradrenaline levels are not correlated with the plasma concentration of the drug. 4. The changes in plasma noradrenaline concentrations support a peripheral rather than central mechanism of action of beta-adrenoceptor blockers in man.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7356889      PMCID： PMC1429915          DOI： 10.1111/j.1365-2125.1980.tb04792.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  7 in total

1.  A sensitive radioenzymatic assay for norepinephrine in tissues and plasma.

Authors:  D P Henry; B J Starman; D G Johnson; R H Williams
Journal:  Life Sci       Date:  1975-02-01       Impact factor: 5.037

2.  Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol.

Authors:  C E POWELL; I H SLATER
Journal:  J Pharmacol Exp Ther       Date:  1958-04       Impact factor: 4.030

3.  Effects of clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man.

Authors:  L M Wing; J L Reid; C A Hamilton; P Sever; D S Davies; C T Dollery
Journal:  Clin Sci Mol Med       Date:  1977-07

4.  Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man.

Authors:  C R Lake; M G Ziegler; I J Kopin
Journal:  Life Sci       Date:  1976-06-01       Impact factor: 5.037

5.  Sympathetic nervous function and renin activity in hypertensives on long term drug treatment with propranolol, methyldopa or bendrofluazide.

Authors:  G Polak; J L Reid; C A Hamilton; D H Jones; C T Dollery
Journal:  Clin Exp Hypertens       Date:  1978       Impact factor: 1.749

6.  Treatment of hypertension with propranolol.

Authors:  B N Prichard; P M Gillam
Journal:  Br Med J       Date:  1969-01-04

7.  Increased plasma noradrenaline concentrations in essential hypertension and their decrease after long-term treatment with a beta-receptor-blocking agent (prindolol).

Authors:  H M Brecht; F Banthien; W Ernst; W Schoeppe
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12
  7 in total
  4 in total

1.  The effect of captopril and propranolol on the responses to posture and isometric exercise in patients with essential hypertension.

Authors:  M J Vandenburg; J M Holly; F J Goodwin; V L Sharman; F P Marsh
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Effect of propranolol on noradrenaline kinetics in patients with essential hypertension.

Authors:  M Esler; G Jackman; P Leonard; H Skews; A Bobik; G Jennings
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

3.  Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension.

Authors:  J C Petrie; T A Jeffers; O J Robb; A K Scott; J Webster
Journal:  Br Med J       Date:  1980-06-28

4.  Effects of acute and long-term beta-adrenoceptor blockade with propranolol on haemodynamics, plasma catecholamines and renin in essential hypertension.

Authors:  M A van Baak; T L Kho; H Thijssen; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.